Mufg Securities Americas Inc. Purchases 6,701 Shares of Boston Scientific Corporation $BSX

Mufg Securities Americas Inc. grew its holdings in Boston Scientific Corporation (NYSE:BSX) by 25.7% in the second quarter, HoldingsChannel reports. The fund owned 32,789 shares of the medical equipment provider’s stock after buying an additional 6,701 shares during the period. Mufg Securities Americas Inc.’s holdings in Boston Scientific were worth $3,522,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Evelyn Partners Investment Management LLP raised its stake in Boston Scientific by 289.1% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 5,070 shares of the medical equipment provider’s stock worth $496,000 after purchasing an additional 3,767 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at approximately $1,046,000. Journey Strategic Wealth LLC boosted its stake in shares of Boston Scientific by 97.4% in the second quarter. Journey Strategic Wealth LLC now owns 6,469 shares of the medical equipment provider’s stock valued at $695,000 after buying an additional 3,192 shares during the period. Franklin Resources Inc. grew its position in Boston Scientific by 1.8% during the second quarter. Franklin Resources Inc. now owns 7,584,680 shares of the medical equipment provider’s stock worth $814,670,000 after buying an additional 135,266 shares in the last quarter. Finally, Mediolanum International Funds Ltd increased its stake in Boston Scientific by 24.4% during the 2nd quarter. Mediolanum International Funds Ltd now owns 525,994 shares of the medical equipment provider’s stock worth $56,034,000 after acquiring an additional 103,124 shares during the period. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 175,782 shares of company stock worth $17,742,314 in the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Up 0.2%

BSX opened at $96.77 on Friday. The company’s 50 day moving average is $98.97 and its 200-day moving average is $102.38. The company has a market cap of $143.46 billion, a P/E ratio of 51.75, a PEG ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 1-year low of $85.98 and a 1-year high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm’s revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BSX. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. UBS Group upped their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a report on Wednesday, October 22nd. Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Finally, Wells Fargo & Company increased their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.